Physicochemical, Predicted ADME, and Structural Positioning of Azelaic Acid Within an Endocrine Oncology Reference Framework

Background: Azelaic acid, an established dermatologic dicarboxylic acid, was previously nominated as an unusual anticancer repurposing candidate. However, it remains unclear whether physicochemical properties, predicted ADME, or structural proximity to established endocrine anticancer drugs support this hypothesis. This study positioned azelaic acid relative to a clinically anchored endocrine anticancer reference panel using reference-defined space based on physicochemical and predicted ADME descriptors and two-dimensional structural similarity analyses. Methods: Sixteen clinically used endocrine anticancer drugs defined the reference set, with finasteride and dutasteride included as mechanistic comparators. SwissADME descriptors were screened for redundancy, standardized, and analyzed by principal component analysis and Euclidean nearest neighbor distances. Robustness was assessed by leave-one-reference-out, bootstrap, and WLOGP sensitivity analyses. Structural similarity was evaluated independently using Morgan fingerprints and Tanimoto coefficients. Results: The first two principal components explained 75.31% of reference variance. Flutamide was the nearest Clinical Reference to azelaic acid in physicochemical and predicted ADME space (d = 3.0063), but this distance exceeded the reference q90 threshold (2.6521), classifying azelaic acid as extrapolative. This classification persisted in all 16 leave-one-reference-out analyses and in 73.69% of 992 valid bootstrap replicates. Structurally, the highest reference similarity was observed with toremifene (T = 0.08696), below the minimum internal Clinical Reference nearest-neighbor similarity (0.13761); radius-3 sensitivity analysis preserved this result. Conclusions: Azelaic acid is neither a close structural analog nor a physicochemical and predicted ADME neighbor of established endocrine anticancer drugs. Its network-derived nomination therefore represents a non-canonical repurposing hypothesis requiring further experimental validation.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-10-15
DOI
https://doi.org/10.3390/ph19101634
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Physicochemical, Predicted ADME, and Structural Positioning of Azelaic Acid Within an Endocrine Oncology Reference Framework

Mirela Voicu, Lucreția Udrescu, Mirela F. Nicolov, Adrian Voicu et al.
Pharmaceuticals
Computational Drug Discovery Methods
article

Physicochemical, Predicted ADME, and Structural Positioning of Azelaic Acid Within an Endocrine Oncology Reference Framework

Mirela Voicu, Lucreția Udrescu, Mirela F. Nicolov, Adrian Voicu, Daiana Colibăşanu, Elena-Daniela Jurj
article en

Abstract

Background: Azelaic acid, an established dermatologic dicarboxylic acid, was previously nominated as an unusual anticancer repurposing candidate. However, it remains unclear whether physicochemical properties, predicted ADME, or structural proximity to established endocrine anticancer drugs support this hypothesis. This study positioned azelaic acid relative to a clinically anchored endocrine anticancer reference panel using reference-defined space based on physicochemical and predicted ADME descriptors and two-dimensional structural similarity analyses. Methods: Sixteen clinically used endocrine anticancer drugs defined the reference set, with finasteride and dutasteride included as mechanistic comparators. SwissADME descriptors were screened for redundancy, standardized, and analyzed by principal component analysis and Euclidean nearest neighbor distances. Robustness was assessed by leave-one-reference-out, bootstrap, and WLOGP sensitivity analyses. Structural similarity was evaluated independently using Morgan fingerprints and Tanimoto coefficients. Results: The first two principal components explained 75.31% of reference variance. Flutamide was the nearest Clinical Reference to azelaic acid in physicochemical and predicted ADME space (d = 3.0063), but this distance exceeded the reference q90 threshold (2.6521), classifying azelaic acid as extrapolative. This classification persisted in all 16 leave-one-reference-out analyses and in 73.69% of 992 valid bootstrap replicates. Structurally, the highest reference similarity was observed with toremifene (T = 0.08696), below the minimum internal Clinical Reference nearest-neighbor similarity (0.13761); radius-3 sensitivity analysis preserved this result. Conclusions: Azelaic acid is neither a close structural analog nor a physicochemical and predicted ADME neighbor of established endocrine anticancer drugs. Its network-derived nomination therefore represents a non-canonical repurposing hypothesis requiring further experimental validation.

PharmaceuticalsVol. 19(10)
Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
Good health and well-being
Openalex Percentile: Top 14%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.